@article{b603841b811f4d0f92e3b6d5ce6d5149,
title = "Building a Resilient Scientific Network for COVID-19 and beyond",
abstract = "The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates that the global scientific community monitor, assess, and respond to the evolving coronavirus disease (COVID-19) pandemic. But the current reactive approach to emerging variants is ill-suited to address the quickly evolving and ever-changing pandemic. To tackle this challenge, investments in pathogen surveillance, systematic variant characterization, and data infrastructure and sharing across public and private sectors will be critical for planning proactive responses to emerging variants. Additionally, an emphasis on incorporating real-time variant identification in point-of-care diagnostics can help inform patient treatment. Active approaches to understand and identify “immunity gaps” can inform design of future vaccines, therapeutics, and diagnostics that will be more resistant to novel variants. Approaches where the scientific community actively plans for and anticipates changes to infectious diseases will result in a more resilient system, capable of adapting to evolving pathogens quickly and effectively.",
keywords = "coronavirus, immunology, vaccines",
author = "Babady, {N. Esther} and Burckhardt, {Rachel M.} and Florian Krammer and Moore, {Penny L.} and Enquist, {Lynn W.}",
note = "Funding Information: P.L.M. is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa, the SA Medical Research Council SHIP program, and the Bill and Melinda Gates Foundation, through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program. Funding Information: N.E.B. acknowledges funding for genomic surveillance of SARS-CoV-2 from the Byrne Family COVID-19 Fund. This work was also funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support (P30 CA008748). Funding Information: SARS-CoV-2 work in the Krammer laboratory is supported by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, the NCI Serological Sciences Network (SeroNet) (under Contract No. 75N91019D00024, Task Order No. 75N91021F00001), NCI U54 CA260560, NIAID HIPC VIVA Grant AI168631, as well as institutional funding. Publisher Copyright: {\textcopyright} 2022 Babady et al.",
year = "2022",
month = sep,
doi = "10.1128/mbio.02223-22",
language = "English",
volume = "13",
journal = "mBio",
issn = "2161-2129",
publisher = "American Society for Microbiology",
number = "5",
}